Check-Cap Ltd. Announces $10M Registered Direct Offering
Check-Cap Ltd. Announces $10M Registered Direct Offering
ISFIYA, Israel, March 1, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (CRC), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 20,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to an aggregate of 15,000,000 of the Company's ordinary shares in a registered direct offering. Each ordinary share is being sold together with one warrant to purchase 0.75 ordinary share at a combined offering price of $0.50 per ordinary share and accompanying warrant. The warrants will have a term of five years following the date of issuance, be exercisable immediately and have an exercise price of $0.65 per ordinary share. The registered direct offering is expected to close on or about March 3, 2022, subject to satisfaction of customary closing conditions.
ISFIYA, Israel, March 1, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (CRC), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 20,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to an aggregate of 15,000,000 of the Company's ordinary shares in a registered direct offering. Each ordinary share is being sold together with one warrant to purchase 0.75 ordinary share at a combined offering price of $0.50 per ordinary share and accompanying warrant. The warrants will have a term of five years following the date of issuance, be exercisable immediately and have an exercise price of $0.65 per ordinary share. The registered direct offering is expected to close on or about March 3, 2022, subject to satisfaction of customary closing conditions.
以色列 ISFIYA,2022 年 3 月 1 日/新聞通訊社/-檢查帽有限公司(「公司」或「檢查帽」)(NASDAQ:CHEK),一家臨床階段醫學診斷公司,推進 C-Scan® 的開發,首個也是唯一一個對患者友好的免準備篩查,可以在轉化為結腸癌之前檢測到結腸癌(CRC), 今天宣布已與多名機構和認可投資者簽訂確定協議,以購買和出售該公司 20,000,000 股普通股及隨附認股權證於登記直接發售中購入本公司合共 15,000,000 股普通股。每股普通股將連同一份認股權證一併出售,購買 0.75 股普通股,合併發售價為每股普通股 0.50 美元及隨附認股權證。認股權證的期限為發行日期後的五年,可立即行使,行使價為每股普通股 0.65 美元。註冊的直接發行預計將於 2022 年 3 月 3 日左右結束,但須符合慣常結束條件。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧